Wenbo Xu

Dr. Wenbo Xu

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
RJRuidi Jiao
Ruidi Jiao
HLHui Luo
Hui Luo
WXWenbo Xu
Wenbo Xu
HGHong Ge
Hong Ge
Esophageal squamous cell carcinoma (ESCC) is one of the common malignant tumors in the world. More than half of patients with ESCC were detected in advanced or metastatic disease at the time of initial diagnosis and lost the opportunities of surgery. Currently, surgical resection, radiotherapy, and chemotherapy are most utilized in clinical practice, however, they are associated with limited survival benefits. Recognition of the limitation of traditional antitumor strategies prompt the development of new means to treat human cancer. In recent years, studies on immune checkpoint inhibitors (eg PD-1/PD-L1 inhibitors, CTLA-4 inhibitors, etc.) in ESCC have shown promising results. In addition, the combination of immune checkpoint inhibitor and traditional antitumor strategies for ESCC has caused extensive interest, and the results are encouraging. Previous analysis indicated that tumor cell PD-L1 expression, tumor mutation load (TMB), microsatellite instability-high status (MSI-H), and other biomarkers have relatively correlated with the efficacy of immunotherapy. This review explores the recent studies investigating checkpoint inhibitors in ESCC.

1 January 2021 in Evolutionary Bioinformatics
Verified
Journal Article
Open access
PDF file
XLXuan Luo
Xuan Luo
LFLei Feng
Lei Feng
WXWenbo Xu
Wenbo Xu
Xuejing BaiXuejing Bai
Xuejing Bai
MWMengNa Wu
MengNa Wu
Lung adenocarcinoma (LUAD) is a tumor with high incidence. This study aimed to identify the central genes of LUAD. LUAD were analyzed by weighted gene co-expression network (WGCNA), and differentially expressed genes (DEGs) were identified. Samples were obtained from The Cancer Genome Atlas (TCGA) and Genotype Tissue Expression (GTEx) databases and included 515 LUAD samples and 347 normal samples. The WGCNA algorithm generated a total of 10 modules. The top 2 modules (MEturquoise and MEblue) with the highest correlation to LUAD were selected. Ten Hub genes (IL6, CDH1, PECAM1, SPP1, THBS1, HGF, SNCA, CDH5, CAV1, and DLC1) were screened in the intersecting genes of DEGs and WGCNA (MEturquoise and MEblue). Only SPP1 was correlated with LUAD poor survival, indicating that SPP1 may be a key Hub gene for LUAD. The competing endogenous RNA (ceRNA) network was constructed to analyze the regulatory relationship of Hub genes, and SPP1 may be directly regulated by 4 microRNAs (miRNAs) and indirectly regulated by 49 long noncoding RNAs (lncRNAs).

13 August 2024 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
WXWenbo Xu
Wenbo Xu
SLShuai Liu
Shuai Liu
LMLongtu Ma
Longtu Ma
LCLong Cheng
Long Cheng
QLQingchao Li
Qingchao Li
ZDZhilong Dong
Zhilong Dong

31 October 2020 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
YZYunlai Zhi
Yunlai Zhi
XLXiao Li
Xiao Li
FQFeng Qi
Feng Qi
XHXin Hu
Xin Hu
WXWenbo Xu
Wenbo Xu
The purpose of this article was to explore the association of tumor size with lymph node metastases (LNM) risk in patients with clear cell renal cell carcinoma (ccRCC). Based on the Surveillance, Epidemiology, and End Result (SEER) database, patients diagnosed with ccRCC from 1988 to 2015 were included in this study. For each patient, personal characteristics, clinicopathological data, and survival outcomes were, respectively, collected. Subsequently, the odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to investigate the potential risk factors for LNM in ccRCC. Finally, Kaplan-Meier (KM) survival plots of overall survival (OS) and ccRCC-specific survival (CSS) were evaluated on the basis of different tumor sizes. A total of 8,292 patients were finally enrolled in the study, 1,170 of whom (14.11%) had LNM. According to the heatmap, we could intuitively interpret that larger tumor size was related to an increased risk of LNM obviously. The risk of LNM was evidently greater for larger tumor size (4-7 cm: OR = 2.415, 95% CI = 1.708–3.415; 7–10 cm: OR = 3.746, 95% CI = 2.677–5.242; and >10 cm: OR = 4.617, 95% CI = 3.302–6.457) compared with smaller tumor size (≤4 cm). According to the KM survival plots of OS and CSS, we observed a gradual decline in survival with increasing tumor size, while the smallest tumor size had the best survival outcomes. These results indicated the positive relationship of tumor size with risk of LNM in ccRCC. And we also noticed continual decrease survival rates of OS and CSS with increasing tumor size.

1 March 2020 in Precision Medical Sciences
Verified
Journal Article
Open access
PDF file
WXWenbo Xu
Wenbo Xu
FQFeng Qi
Feng Qi
RJRuidi Jiao
Ruidi Jiao
LZLizhuan Zheng
Lizhuan Zheng
YZYinghao Zhang
Yinghao Zhang
ZKZhengjun Kang
Zhengjun Kang
Background: This meta‐analysis was performed to clarify the prognostic role of the expression of T‐cell immunoglobulin mucin‐3 (TIM‐3) in different cancer types.Methods: Related articles were searched from PubMed, EMBASE, Web of Science up to December 31, 2019. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were utilized to explore their associations. In addition, we conducted subgroup analyses stratified by various factors.Results: Eventually, a total of 33 studies including 4223 patients were enrolled in this study. Results showed that patients with high TIM‐3 expression had shorter overall survival (OS) (HR = 1.67, 95% CI: 1.37‐2.04) and progression‐free survival (HR = 1.80, 95% CI: 1.14‐2.83), but subgroup analyses indicated there were no relationship between TIM‐3 expression and disease‐free survival or recurrence‐free survival. It was reassuring that high TIM‐3 expression may be associated with poor prognosis in osteosarcoma, gastric cancer, liver cancer, esophageal cancer, and lymphoma, while no prognostic significance was detected of TIM‐3 expression in lung cancer, kidney cancer, or breast cancer. Furthermore, we did not find association of TIM‐3 with any clinicopathological parameters.Conclusions: High TIM‐3 expression might be a potential biomarker which can be used to predict the poor prognosis of different cancer types, especially osteosarcoma, gastric cancer, liver cancer, esophageal cancer, and lymphoma.

1 April 2020 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
WXWenbo Xu
Wenbo Xu
FQFeng Qi
Feng Qi
YLYi Liu
Yi Liu
LZLizhuan Zheng
Lizhuan Zheng
ZKZhengjun Kang
Zhengjun Kang
Background: To develop and validate prognostic nomograms for predicting overall survival (OS) and cancer-specific survival (CSS) in patients with penile cancer (PC). Methods: Based on the Surveillance, Epidemiology, and End Result (SEER) database, patients diagnosed with PC from 2010 to 2015 were enrolled in this study. For each patient, clinical characteristics and survival results were respectively collected. With the method of random-number generation, included patients were divided into the training cohort and the validation group. Subsequently, nomograms were constructed to predict 3‐ and 5‐year OS and CSS based on the results of multivariate analyses. Kaplan-Meier (KM) method and the log-rank test were used to estimate survival curves of each variables. Finally, the calibration plots, concordance index (C-index), area under the receiver operating characteristic (ROC) curves were used to evaluate nomograms performance. Results: Totally, 1,418 patients were eventually enrolled in the study, including 994 patients in the training cohort and 424 patients in the validation cohort. No significant difference was detected in the baseline characteristics between two cohorts. According to results of the uni- and multivariate analysis in the training cohort, 7 factors (including age, race, T stage, N stage, M stage, histology codes, and the use of surgery) for OS and 7 factors (including race, T stage, N stage, M stage, histology codes, the use of surgery and lymph node removal) for CSS were selected for constructing the nomograms. The C-indices for OS and CSS were 0.755 and 0.805 in the training cohort and 0.711, 0.737 in the validation cohort. In addition, the 3- and 5-year area under the ROC curve (AUC)s for OS were 0.792 and 0.771 in the training cohort, and 0.687 and 0.695 in the validation group. When it came to CSS, it was 0.83 and 0.826 in the training cohort and 0.758 and 0.746 in the validation cohort. Lastly, the calibration curves indicated a good consistency between the actual survival and the predictive survival. Conclusions: We firstly established survival models to predict OS and CSS in PC patients with good predictive ability. Further studies are needed to validate our results before clinical application in the future.